Sunday, August 05, 2018 4:33:18 PM
In other word you want a drug to ineffective at producing ROS under normal conditions.
The authors of the Goguadze study say much of the same but in more detail and technical terms.
Such ROS increase,
generated by inducing s1R activity in normal conditions,
could constitute a physiological signal. Indeed, ROS function
as mediators of signal transduction by triggering redox regulation
of proteins, enzymes, and ion channels (Angelova and
Abramov 2016) and may constitute a method of communication
between mitochondrial function and other cellular processes
to maintain cell homeostasis and promote cell adaptation
to stress (Sena and Chandel 2012). Different sites of mitochondrial
ROS production have distinct signaling roles and
the primary production sites likely change under different
physiological conditions (Sena and Chandel 2012). For instance,
ROS phosphorylated epidermal growth factor (EGF)
and platelet-derived growth factor (PDGF) receptors, thus
mimicking growth factor-induced signaling (Miller et al.
1994; Gamou and Shimizu, 1995). H2O2 activated phospholipases,
including cytosolic PLA2, which has been shown to
be translocated to the membrane fraction in a calciumindependent
fashion and concomitantly activated (van
Rossum et al. 2004). ROS signaling modulates ion channel
function, including BK, KCN, ERG, or TRP channels, and
consequently regulates neuronal excitability (Angelova and
Abramov 2017). ROS induction also triggers cytoprotective
pathways and, for instance, ROS are potent regulators of the
Bcl-2 expression via both transcription and protein degradation
(Hildeman et al. 2003; Li et al. 2004). ROS decrease the
expression of Bcl-2 mRNA by promoting CRE-binding protein
or NF-?B to CRE and ?B sequences on the Bcl-2 promoter
or by facilitating protein degradation (Sohur et al. 1999;
Pugazhenthi et al. 2003; Li et al. 2004). Interestingly, s1Rs
have previously been shown to promote cell survival in part
by transcriptionally regulating Bcl-2 expression via the ROS/
NF-?B pathway, since knockdown of s1Rs potentiated H2O2-
induced apoptosis in CHO cells (Meunier and Hayashi 2010).
It therefore appears that oxidative stress is a major component
of physiological s1R activity.
Mitochondrial ROS can be generated through different
mechanisms and the beneficial or damaging effects of ROS
are initiated when they target distinct molecules and consequently
begin functioning as part of complex signal transduction
pathways. Various ROS have different physical and
chemical properties that allow them to modify distinct target
molecules. The reduction-oxidation-dependent signaling system
is highly conserved and based on the oxidation and
reduction of cysteine residues. Experimental evidence suggests
that ROS generation causes reversible posttranslational
modification, not only of cysteine residues but
also of selenocysteine, methionine, and histidine residues
(Johnson 2011). Although the mechanisms underlying ROS
signaling are not fully understood, at individual mitochondria
level, ROS may trigger opening of mitochondrial permeability
transition pore (mPTP) in intact cell systems. The phenomenon
of ROS-triggered mPTP opening associated with further
stimulation of ROS formation has been termed ROS-induced
ROS release (Zorov et al. 2000). Sources of mitochondrial
ROS include ETC, the mitochondrial matrix and enzymes of
the tricarboxylic acid cycle (TCA), or, for instance, the outer
membrane enzyme monoamine oxidase (for reviews, Tahara
et al. 2009; Angelova and Abramov 2016).
As for your points about A2-73 showing some positive effects in mitigating oxidative stress, I did not go over them closely but I expect you've faithfully reproduced parts of the text. My point has always been that overall it underperforms. I never said that it had no effects whatsoever...that was someone else falsely ascribing that view to me.
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
